3RICHARDSON G, BARLOGIE B, BERENSON J, et al. A phase Ⅱ study of bortezomib in relapsed, refractory myeloma[J ]. N Engl J Med, 2003, 348(26) : 2609 -2617. 被引量：1
4MITSIADES N, MITSIADES CS, RICHARDSON PG, et al The proteasome inhibitor PS--341 potenciates sensitivity of mul tiple myeloma cells to conventional chemotherapeutic agents therapeutic applications[J]. Blood,2003, 101(6): 2377-2380 被引量：1
5RICHARDSON G, SONNEVELD P, SCHUSTER MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma[J]. N Engl J Med,2005,352(24) : 2487 - 2498. 被引量：1
6BOOCCADORO M, MORGAN G, CAVENAGH J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy [ J ]. Cancer Int, 2005,5 ( 1 ) : 18 -27. 被引量：1
7BLADE J, SAMSON D, REECE D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation[ J ]. Br J Haematol, 1998,102 (5) : 1115 - 1123. 被引量：1
8周际昌主编..实用肿瘤内科学[M].北京:人民卫生出版社,1999:639.
9WU KL, WIERNGEN W, VELLENGA E, et al. Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice[J]. Haematologica, 2005,90 (7) : 996 - 997. 被引量：1
10JONES JO, ARVIN AM. Inhibition of the NF- kB pathway by varicellazoster virus in vitro and in human epidermal cells in vivo [] ]. Journal of virology, 2006,80 ( 11 ) :5113 - 5124. 被引量：1
